Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the premium price of Centocor Ortho Biotech/Janssen-Cilag's Stelara and Abbott's briakinumab will drive robust sales for both of these interleukin (IL)-12/IL-23 inhibitors in 2018 in the United States, France, Germany, Italy, Spain and the United Kingdom.

The Pharmacor 2010 findings from the topic entitled Crohn's Disease reveals that Stelara will earn sales of nearly $337 million in 2018, following its launch for the indication in 2014 in the U.S. and Europe. Briakinumab, which is also expected to be priced at a significant premium over other marketed biologics for Crohn's disease, will earn just over $130 million in 2018. Briakinumab will launch for the indication in 2015 in the U.S. and in Europe. Although Stelara and briakinumab will achieve robust sales, neither agent is expected to garner substantial patient share.

"Following the approval of Stelara for psoriasis last year, ongoing clinical trials have revealed that Crohn's disease patients will likely require a dose of Stelara which is twice as large as the dose used in psoriasis treatment--a dosing scenario such as this will translate into a premium price, which will heavily constrain the use of Stelara and other IL-12/IL-23 inhibitors among Crohn's disease patients," said Decision Resources Analyst Kathryn Benton. "However, despite minimal uptake following their launches, the high price of Stelara and briakinumab will contribute to healthy sales for both agents."

The Pharmacor 2010 findings also reveal that, following a recent clinical development setback for UCB/Otsuka's Cimzia, Decision Resources has revised its previously forecasted European and Japanese launch dates for Cimzia. In December 2009, UCB announced that Cimzia failed to achieve the primary measure of clinical efficacy--induction of remission--in a Phase III clinical trial for Crohn's disease. Cimzia, which is now expected to launch for the indication in Europe in 2014 and in Japan in 2016, is forecast to earn $211 million in 2018 in acute and maintenance treatment of Crohn's disease.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

  registered trademarks of their respective holders.     For more information, contact:    Decision Resources, Inc.   Christopher Comfort   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, Inc.,

Approval in Japan of New Formulation of Mitsubishi Tanabe Pharma's Edaravone Will Further Bolster its Position as the Top-Selling Therapy for Acute Ischemic Stroke

View Now